Nanomedic Europe OÜ
Nanomedic Europe OÜ is Osaühing. The main activity is Lepinguline toitlustusteenus jm toitlustamine (56221). The company is located in Harju maakond. Founded 12/09/2016. 2024 figures: revenue 7,638 €, profit -4,859 €, employees 0. Taxes for I quarter of 2025 were 17 €. No tax debt.
Key figures
- Year
- 2024
- Revenue
- 7,638 €
- Net profit
- -4,859 €
Signals
Financials
2024: revenue 7,638 €, net profit -4,859 €.